Connective Issue #13

MIB News
Connective Issue #13

Volume 13 | September 6, 2023

All The Ways We Can Make It Better Together

As we usher in Childhood Cancer Awareness Month this September, we are grateful for all the joint advocacy efforts, the media attention, and global support to raise awareness for childhood cancers. But even more so, we are grateful to everyone in our community who shines a light on this disease and works tirelessly to make it better every day of every month.  Here's the news:

Joel Madden is our new MIB Agents Brand Ambassador and we could not be more excited to welcome him to our team!    

The Greenfield Lab at Indiana University, our spotlight this month, is making it better with several research projects dedicated to improving osteosarcoma treatments and outcomes.  

Lori Krause, Grief Coach is leading 39 Healing Hearts sessions this fall for bereaved family members.

Dr. Michael Bishop discusses AOST2023, the first national osteosarcoma clinical trial in 20 years, which is now open and recruiting.

YOU can make it better this month by supporting our Gold Bow fundraiser.

Thank you for being part of our community and making it better with us.

With hope,


Save The Date

Our Community

Joel Madden Makes It Better

MIB Agents is thrilled to welcome Joel Madden to our team as a Brand Ambassador!  Joel is best known as the lead vocalist for the rock band Good Charlotte, and host of the Artist Friendly podcast.  He is also part of the pop rock collaboration the Madden Brothers with his identical twin brother Benji Madden.  No stranger to using his powers for good, he is a UNICEF Goodwill Ambassador and contributed to "We Are the World 25 for Haiti." Madden was one of the four vocal coaches on the The Voice (Australia), and recently served as host of Ink Master. Joel already has a track record of making it better for the osteosarcoma community, appearing on Celebrity Wheel of Fortune to win nearly $200,000 for MIB Agents and hosting MIB Agents osTEAo co-host, Mia Sandino on his podcast. Please join us in welcoming @JoelMadden to the MIB Agents family!

Gold Bows for Childhood Cancer Awareness

Adorn your mailbox, front door, office, or any special place with a gold bow to support pediatric cancer patients and raise awareness in your community during Childhood Cancer Awareness month in September! You can make it better by ordering a bow with a $25 donation and/or volunteering as a Bow Agents to distribute bows in your community.

Order Your Bow Online

Get Your Bow Locally

Sign Up to Be a Bow Agent

Get Your Limited Edition Osteo ERAS Shirt!

An ancient disease, osteosarcoma has been found in dinosaur bones and mummies. Unfortunately, the standard treatment is also old and hasn't changed in 40 years. In the US, over 10,000 dogs and 900 humans are diagnosed with osteosarcoma each year. Get your shirt to raise awareness and funds for osteosarcoma programs, education, and research. T-shirts are available in 5 colors and sweatshirts are available in 4 colors.

Order Osteo ERAS Gear

Spotlight on the Greenfield Lab

The Greenfield Lab at the Indiana University School of Medicine has long-standing research interests focused on basic and translational aspects of bone biology, and on osteosarcoma metastasis. Three of the current osteosarcoma projects include 1) focusing on repurposed drugs that are FDA-approved for other cancers, 2) evaluating how well sarcosphere responses mimic in vivo responses, and 3) studying a novel antibacterial agent called halicin to see if it is effective against bacterial biofilms in vitro and in mice.

Read More About the Greenfield Lab

Career Connection

  1. Senior Research Technician - Majzner Pediatrics Lab
  2. Myrovlitis Trust Senior Research Officer
  3. Myrovlitis Trust Health Information and Engagement Manager
  4. Postdoc position MERLN | 3D Printing and Bioprinting on advanced osteosarcoma’s predictive models (PREDICTOS, Horizon Europe project)
  5. Postdoctoral and staff scientists in the Curtis Lab at Stanford Medicine
  6. Behavioral Health Staff Scientist in the Psychosocial Support and Research Program, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health (NIH)

If you have a job posting and you would like it included here, please email


OsteoBites Webinar Series

Sept 14 | Fiona Freeman, PhD
Addressing the unmet scientific challenges in osteosarcoma treatment through innovative engineering techniques
Sept 21 | osTEAo AYA podcast
Tea Spill: AYA Cancer Gab Sesh
Sept 28 | Matteo Trucco, MD and Kurt Weiss, MD
Repurposing Disulfiram to overcome chemotherapy resistance in relapsed sarcomas
Oct 5 | Jim Palma, TargetCancer Foundation
TCF-001 TRACK (Target Rare Cancer Knowledge): A Clinical Trial Studying Precision Medicine in Rare Cancers

Watch Past Episodes and See the Upcoming Schedule

Tumor Review Board for Osteosarcoma

A virtual tumor review board for osteosarcoma, TURBO is open to global clinicians or researchers with an interest in osteosarcoma.  Patients and families are welcome to ask their oncologists to present a case on their behalf.  Join TURBO to request an invite or submit a case.

Next meeting: September 13th at 5pm ET


Osteosarcoma in the News


Healing Hearts New Sept - Dec Sessions!

Grief coach Lori Krause is back in September to continue her wonderful work with MIB Agents Healing Hearts! Email to learn more.  

Healing Hearts for Bereaved Parents

If you have registered for HH within the past year, you do not have to re-register.  You can attend either class as you need.

Sundays at 8:30 PM ET: 9/10 - 12/10 (no session on 10/22 and 11/26)

Wednesdays at 7:00 PM ET: 9/13-12/13 (no session on 11/22)

Healing Hearts for Teen Siblings (ages 12-16)

Sundays at at 7:00 PM ET: 9/10, 9/24, 10/8, 11/5, 11/19, 12/3, 12/17

Healing Hearts for Young Adult Siblings (ages 17-30)

Sundays at at 7:00 PM ET: 9/17, 10/1, 10/15, 10/29, 11/12, 12/10, 12/17

Sign Up for Healing Hearts


New Clinical Trial Cabozantinib & MAP for Osteosarcoma

The first national osteosarcoma clinical trial in 20 years, AOST2023 -  A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma is now open and recruiting. The first phase is currenlty recruiting newly diagnosed patients with a resectable primary tumor and metastatic disease. For more information about the study, please contact study protocol coordinator Julie Duarte, MPH.

Funding Opportunity Osteosarcoma Institute

The OSI Grant Cycle Information Session will be on September 13th from 2-3pm CT.  During this session, OSI will review their two-stage grant process, review FAQs from previous grant cycles, highlight changes to their 2023-24 grant process, and answer questions from the audience. No need to register, you can access the session with this zoom link. (Meeting ID: 879 1461 5228 / Passcode: OSI). If you can't attend live, the session will be recorded and posted to the OSI's YouTube channel.  The 2023 Call for Letters of Intent will be posted in early September, and submissions will be due on November 15, 2023.

If you have a trial that is currently enrolling osteosarcoma patients, please email

All MIB Agents programs are free of charge, thanks to our generous donors who Make it Better.

Please consider a donation to support osteosarcoma patient programs, education, and research.


Other blog posts